Mario Boccadoro Selected Research

Lenalidomide (CC 5013)

12/2023	Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
10/2023	Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.
10/2022	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
10/2022	Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma.
3/2022	Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
1/2022	Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial.
1/2022	Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
12/2021	Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
11/2021	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.
7/2021	Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mario Boccadoro Research Topics

Disease

160	Multiple Myeloma 12/2023 - 06/2002
34	Neoplasms (Cancer) 06/2021 - 04/2003
15	Neutropenia 10/2023 - 04/2009
14	Infections 12/2023 - 08/2007
13	Residual Neoplasm 01/2023 - 04/2003
10	Disease Progression 10/2023 - 06/2005
9	Hematologic Neoplasms (Hematological Malignancy) 03/2019 - 10/2002
6	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 06/2021 - 01/2006
6	Anemia 01/2018 - 06/2004
6	Lymphoma (Lymphomas) 01/2018 - 04/2003
5	Thrombocytopenia (Thrombopenia) 10/2023 - 01/2006
5	Chemotherapy-Induced Febrile Neutropenia 06/2019 - 01/2016
5	Renal Insufficiency (Renal Failure) 10/2018 - 06/2004
5	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2016 - 06/2004
4	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 08/2014 - 05/2004
4	Peripheral Nervous System Diseases (PNS Diseases) 06/2014 - 01/2006
4	Thromboembolism 03/2011 - 10/2005
3	Pneumonia (Pneumonitis) 10/2023 - 01/2021
3	Immunoglobulin Light-chain Amyloidosis 03/2023 - 01/2018
3	Febrile Neutropenia 06/2019 - 02/2016
3	Monoclonal Gammopathy of Undetermined Significance 01/2018 - 09/2007
3	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 07/2008 - 04/2003
2	Cytopenia 01/2023 - 02/2009
2	COVID-19 01/2023 - 01/2020
2	Frailty 10/2020 - 01/2020
2	Leukemia 01/2020 - 10/2002
2	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 03/2018 - 01/2004
2	Primary Myelofibrosis (Myelosclerosis) 01/2018 - 01/2016
2	Inflammation (Inflammations) 01/2016 - 06/2005
2	Plasma Cell Leukemia 01/2016 - 06/2013
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/2014 - 05/2004
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 11/2013 - 12/2006
2	Osteonecrosis (Kienbock's Disease) 01/2013 - 11/2008

Drug/Important Bio-Agent (IBA)

43	Bortezomib (Velcade)FDA Link 12/2023 - 06/2005
40	Lenalidomide (CC 5013)FDA Link 12/2023 - 07/2007
39	Dexamethasone (Maxidex)FDA LinkGeneric 12/2023 - 01/2004
35	Melphalan (Alkeran)FDA LinkGeneric 11/2023 - 08/2002
35	Thalidomide (Thalomid)FDA Link 12/2021 - 01/2004
30	Prednisone (Sone)FDA LinkGeneric 12/2020 - 10/2005
15	Proteasome InhibitorsIBA 10/2023 - 06/2005
11	daratumumabIBA 12/2023 - 01/2019
11	Monoclonal AntibodiesIBA 12/2023 - 04/2008
11	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2023 - 02/2009
11	carfilzomibIBA 01/2023 - 07/2014
6	pomalidomideIBA 10/2023 - 10/2013
6	Immunomodulating AgentsIBA 09/2021 - 07/2008
6	Filgrastim (Neupogen)FDA Link 06/2019 - 01/2016
6	Biosimilar PharmaceuticalsIBA 06/2019 - 01/2016
5	AntigensIBA 11/2020 - 06/2012
5	Alkylating AgentsIBA 01/2020 - 07/2007
5	SteroidsIBA 01/2020 - 10/2005
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 11/2023 - 02/2006
4	Immunoglobulins (Immunoglobulin)IBA 01/2023 - 01/2005
4	Chimeric Antigen ReceptorsIBA 01/2023 - 01/2019
4	elotuzumabIBA 10/2022 - 01/2021
4	ixazomibIBA 12/2021 - 01/2018
4	OligonucleotidesIBA 01/2019 - 02/2009
4	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 11/2017 - 10/2012
4	Erythropoietin FDA Link 01/2016 - 06/2004
4	Rituximab (Mabthera)FDA Link 11/2013 - 12/2006
3	VaccinesIBA 01/2023 - 08/2007
3	Immunoglobulin M (IgM)IBA 01/2021 - 09/2007
3	Proteins (Proteins, Gene)FDA Link 06/2020 - 10/2014
3	CytokinesIBA 01/2019 - 06/2005
3	liposomal doxorubicin (Doxil)FDA Link 08/2013 - 04/2007
3	Cholecalciferol (Vitamin D3)FDA Link 07/2012 - 05/2004
3	Enoxaparin (Lovenox)FDA LinkGeneric 01/2012 - 03/2006
3	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2012 - 10/2007
3	Proteasome Endopeptidase Complex (Proteasome)IBA 03/2009 - 07/2006
3	AnticoagulantsIBA 04/2008 - 10/2005
3	Hemoglobins (Hemoglobin)IBA 09/2007 - 06/2005
2	Bispecific AntibodiesIBA 01/2023 - 11/2020
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2023 - 01/2018
2	Antiviral Agents (Antivirals)IBA 01/2023 - 01/2023
2	Hypoxia-Inducible Factor 1IBA 06/2021 - 01/2020
2	Phosphotransferases (Kinase)IBA 01/2020 - 01/2016
2	fludarabineIBA 01/2020 - 01/2006
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 12/2010
2	LigandsIBA 01/2018 - 10/2012
2	ruxolitinibIBA 01/2018 - 01/2016
2	Immunoglobulin G (IgG)IBA 01/2018 - 09/2007
2	MicroRNAs (MicroRNA)IBA 06/2013 - 09/2008
2	Diphosphonates (Bisphosphonates)IBA 01/2013 - 11/2008
2	Mevalonic Acid (Mevalonate)IBA 10/2012 - 12/2010

Therapy/Procedure

71	Therapeutics 12/2023 - 08/2002
29	Drug Therapy (Chemotherapy) 03/2023 - 08/2002
26	Stem Cell Transplantation 11/2023 - 10/2002
10	Transplantation 12/2023 - 10/2002
10	Autologous Transplantation 12/2021 - 06/2002
10	Homologous Transplantation 02/2016 - 06/2004
7	Immunotherapy 10/2023 - 06/2005
7	Salvage Therapy 03/2022 - 08/2007
3	Hematopoietic Stem Cell Transplantation 01/2020 - 07/2012
3	Drug Tapering 06/2014 - 04/2008
3	Cell Transplantation 06/2013 - 06/2006
2	Aftercare (After-Treatment) 10/2023 - 11/2017
2	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2019 - 08/2007
2	Radiotherapy 11/2018 - 06/2005
2	Antibiotic Prophylaxis 01/2017 - 11/2008
2	Duration of Therapy 10/2015 - 03/2014